NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/20/2025
Back to search
Official data from USPTO
STARPAX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
STARPAX
ST13
US500000088423029Class
1, 5, 42, 44
Filing
88423029
Registration
7797794
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
05/09/2019
Registration date
05/20/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/20/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
MONTRÉAL, CA
Examiner
WHEATLEY, TRAVIS DWIGHT
Law office
O10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
STARPAX BIOPHARMA INC.
Starpax Medical Inc.
Representatives
Alison M. Caless CANTOR COLBURN LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
active biochemical formulations in the nature of active biochemical ingredients for use in the manufacture of anti-cancer drugs
Class 5
anti-cancer preparations; bacteria capable to transport therapeutic agents and imagery markers into cancer tumors and organs for the treatment of cancer and other diseases requiring targeted delivery; bacteria capable to transport therapeutic agents and imagery markers into organs for the treatment of diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and compositions for the treatment and prevention of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and substances for the treatment of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; therapeutic agents and imagery markers for delivery of cancer treatment
Class 42
Pharmaceutical research and development; medical and scientific researchconducting clinical trials for others for pharmaceutical preparations used for the treatment of cancerimmunologicalinflammatory and infectious diseasespain
Class 44
Health care services for treating cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; medical analysis services for cancer diagnosis and prognosis; medical diagnostic services
Publications
History of USPTO decisions and trademark events.
51 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/20/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/01/2025
PUBO
PUBLISHED FOR OPPOSITION
04/01/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/26/2025
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/11/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
03/10/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/10/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
03/10/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/06/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/06/2025
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/12/2025
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/12/2025
CNSI
SUSPENSION INQUIRY WRITTEN
01/12/2025
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
01/06/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
09/25/2024
DOCK
ASSIGNED TO EXAMINER
08/15/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/15/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/27/2023
GNSL
LETTER OF SUSPENSION E-MAILED
11/27/2023
CNSL
SUSPENSION LETTER WRITTEN
11/27/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/27/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/27/2023
ALIE
ASSIGNED TO LIE
11/26/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/21/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
04/17/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
04/17/2023
CNSI
SUSPENSION INQUIRY WRITTEN
04/17/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
04/13/2023
DOCK
ASSIGNED TO EXAMINER
04/11/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
03/18/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
07/26/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/26/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
07/26/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/25/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
07/24/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/24/2020
GNSL
LETTER OF SUSPENSION E-MAILED
01/24/2020
CNSL
SUSPENSION LETTER WRITTEN
01/24/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/23/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/22/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/22/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/06/2019
GNRT
NON-FINAL ACTION E-MAILED
08/06/2019
CNRT
NON-FINAL ACTION WRITTEN
08/06/2019
DOCK
ASSIGNED TO EXAMINER
07/24/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/29/2019
NWAP
NEW APPLICATION ENTERED
05/13/2019
Continuous trademark protection
Get notified about every new filing that threatens STARPAX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.